I believe that we'll know by tomorrow morning that this action is being driven by either (a) Analyst upgrades / coverage initiation of CUR to some lofty price targets, or (b) some piece of real news on the studies, or FDA, etc.
Just too much volume here for this to be a 'bounceback' off of this mornings gap fill.
Keep in mind here that Institutional ownership in CUR is still relatively low for a small bio.
You are so right Ace,
I have similar thinking. This in abnormal. $3.40 with some volume is to be expected. But not this.
As usual, something is up and those in the know, know it.
Could be the Chinese are buying it up on the stroke results of the first patient treated. It could be the NSI - 189 update. But it feels big, as in, like you say, the FDA.
There is a crescendo of nothing but good news happening.